PatchTheCVECVE-2026-119251: A malicious actor with local access and high privileges could exploit an Improper Access Control vulnerability
CVE-2026-119251 is a medium-severity flaw (CVSS 6.7) affecting affected software. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.
A malicious actor with local access and high privileges could exploit an Improper Access Control vulnerability found in WiFiman Desktop for macOS to escalate privileges on the host device.
Why this priority
- No elevated risk signals yet
No fix is published yet: follow the downgrade or mitigation steps.
Risk facts
| CVSS score | 6.7 (Medium) |
| Attack vector | Local |
| Attack complexity | Low |
| Privileges needed | High |
| User interaction | None |
| EPSS exploit chance | n/a |
| CISA exploited list | No |
| Weakness | CWE-284 |
| Published | 2026-10-29 |
| Last modified | 2026-10-29 |
Last updated 2026-10-29 · Sources: CVE Program, NVD, CISA KEV, EPSS and vendor advisories · How we score
Timeline
- Published CVE record published
- Updated Record last modified
Advisories and coverage
Research and news
- VulDB Recent Entries: CVE-2026-119251 | Ubiquiti WiFiman up to 1.2.x access control 2026-10-29
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.
Quick answers
How do I fix CVE-2026-119251?
No fixed release is listed yet. Watch the vendor advisory and apply any mitigation shown on this page.
Is CVE-2026-119251 being exploited?
CVE-2026-119251 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.
What does CVE-2026-119251 affect?
CVE-2026-119251 affects affected software. Severity is medium (CVSS 6.7). A malicious actor with local access and high privileges could exploit an Improper Access Control vulnerability found in WiFiman Desktop for macOS to escalate privileges on the host device.
How urgent is CVE-2026-119251?
Priority 23/100. No elevated risk signals yet.